Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 + tislelizumab vs tislelizumab + chemotherapy in CLDN18.2-positive gastric/GEJ adenocarcinoma
CTR20260165Phase 3Active
- Sponsor
- LaNova Medicines
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by LaNova Medicines. Started Apr 2026; status: active.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260165.